Table 5.
Engraftment and Transplantation Outcome.
| Characteristic | G-CSF | PEG-G-CSF | P |
|---|---|---|---|
| Graft source, n | <0.001 | ||
| PBSC | 27 | 19 | |
| BM+PBSC | 15 | 64 | |
| Cellular content of infused grafts | |||
| Total nucleated cells, 108/kg | 17.5 (5.5–31.8) | 23.9(12–0,47.0) | <0.001 |
| CD34+ cells, 106/kg | 4.3 (1.2–13.5) | 5.2(2.1–13.5) | 0.011 |
| CD3+CD19- T cells, 108/kg | 2.7 (0.5–7.0) | 2.8(1.2–5.3) | 0.246 |
| CD3+CD4+ Th cells, 108/kg | 1.4 (0.3–3.0) | 1.5(0.3–3.7) | 0.387 |
| CD3+CD8+ Ts cells, 108/kg | 1.0 (0.2–3.2) | 1.1(0.4–2.4) | 0.509 |
| CD3-CD19+ B cells, 108/kg | 0.7 (0.1–1.8) | 0.9(0.2–,1.9) | 0.004 |
| CD3-CD16+CD56+ NK cells, 108/kg | 0.4 (0.2–0.9) | 0.4 (0.1–0.9) | 0.628 |
| CD4+CD25+CD127dim/− Tregs, 106/kg | 3.6 (1.4–10.4) | 4.7 (2.1–7.5) | 0.309 |
| M-MDSC, 106/kg | 32.0 (1.4–126.4) | 66.4 (11. 9–298.0) | <0.001 |
| G-MDSC, 106/kg | 180.6 (3.1–2073.6) | 270.3 (39.9–1812.4) | 0.089 |
| Engraftment, days(range) | |||
| Median ANC | 11 (8–21) | 12 (8–73) | 0.563 |
| Median PLT | 12 (8–28) | 12 (8–46) | 0.802 |
| Graft failure, n (%) | 2 (4.8) | 2 (2.4) | 0.598 |
| GVHD, n (%) | |||
| aGVHD | 20 (48.8) | 38 (45.8) | 0.753 |
| III-IV aGVHD | 12 (29.3) | 6 (7.2) | 0.001 |
| cGVHD | 15 (36.6) | 27 (32.5) | 0.654 |
| Moderate-severe cGVHD | 7 (17.1) | 7 (8.4) | 0.153 |
| 1-year OS,% | 80.5 ± 6.2 | 83.8 ± 4.1 | 0.920 |
| 1-year GRFS,% | 56.1 ± 7.8 | 70.4 ± 5.2 | 0.299 |
| 1-year relapse rate,% | 12.2 ± 0.3 | 11.1 ± 0.1 | 0.477 |
| Death reason, n (%) | .656 | ||
| Relapse | 5(11.9) | 5(6.0) | |
| GVHD | 2 (4.8)* | 6(7.2)** | |
| TA-TMA | 2 (4.8)* | 1 (1.2) | |
| IFD | 1 (2.4) | 1 (1.2) | |
| Other | 1 (2.4) | 3 (3.6) | |
| Infection, n (%) | |||
| Severe bacterial infection | 6 (14.6) | 13 (15.7) | .881 |
| IFD | 6 (14.6) | 10 (12.0) | .686 |
| CMV viremia | 17 (41.5) | 50 (60.2) | .057 |
| CMV Disease | 1 (2.4) | 6 (7.2) | .424 |
| EBV viremia | 35 (85.4) | 68 (81.9) | .800 |
*The two patients underwent TA-TMA before severe GVHD was well controlled.
**Two patients died of GVHD caused by donor lymphocyte infusion after relapse. One patient died of severe chronic liver GVHD.
PBSC, peripheral blood stem cell; M-MDSC, monocytic myeloid-derived suppressor cell; G-MDSC, granulocytic myeloid-derived suppressor cell; ANC, absolute neutrophil count; TA-TMA, transplant-associated thrombotic microangiopathy; IFD, invasive fungal disease.